Informations

The CALYPSO study offers valuable insights into the effectiveness of durvalumab (PD-L1 inhibitor) plus savolitinib (MET inhibitor) (D+S) in MET-driven advanced papillary renal cancer (aPRC). At 41 months follow-up, MET-driven…

The TOPAZ-1 study has provided valuable insights into the role of plasma circulating tumor DNA (ctDNA) testing in detecting clinically actionable alterations (CAAs) in advanced biliary tract cancer (BTC). While…

At SABCS 2024, Dr. Matteo Lambertini shared insights from a major international study examining the role of risk-reducing mastectomy (RRM) and salpingo-oophorectomy (RRSO) in young BRCA carriers with breast cancer. The study, which analyzed data from 5,290 patients across 109 centers worldwide, offers a deeper understanding of how these surgeries impact long-term survival.

At SABCS 2024, Professor Ian Kunkler presented the 10-year results of the SUPREMO trial, a phase III study evaluating the role of postmastectomy radiotherapy (PMRT) in intermediate-risk breast cancer. The trial aimed to determine whether PMRT improves overall survival in patients with 1-3 positive lymph nodes or high-risk node-negative disease.

At SABCS 2024, Dr. Icro Meattini presented a preplanned interim analysis of the EUROPA trial, a randomized phase III study comparing exclusive endocrine therapy (ET) vs. radiation therapy (RT) in women aged 70+ with luminal-like early breast cancer. The study aimed to evaluate quality of life (HRQOL) and ipsilateral breast tumor recurrence (IBTR) to guide…

Throwback to SABCS 2024, where Dr. Mafalda Oliveira presented findings from the SOLTI VALENTINE phase II trial, evaluating HER3-DXd alone or in combination with letrozole as a neoadjuvant treatment for high-risk HR+/HER2-negative early breast cancer (EBC). The study explored whether HER3-DXd could serve as an effective and tolerable alternative to standard multi-agent chemotherapy.